Pharmaceutical Technology

AUGUST 16, 2022

Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.

Food and Drug Administration 59

Food and Drug Administration Sales Patients Food 59

PM360

SEPTEMBER 21, 2023

This article covers some of the reasons these drugs were chosen, how the process for price negotiation will occur, and the impact for the industry and for patients. Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Pharmaceutical Technology

DECEMBER 11, 2022

Richter’s transformation (RT) is a rare blood cancer arising in up to 10% of patients with chronic lymphocytic leukemia (CLL) and presenting as aggressive lymphoma, typically as diffuse large B-cell lymphoma (DLBCL). Among the enrolled patients, 68 were previously treated and seven were newly diagnosed. The mOS was 13.1

FDA 59

FDA Patients Safety Pharmaceutical 59

Pharmaceutical Technology

SEPTEMBER 2, 2022

This is a result of intensive research efforts that have produced regimens that have prolonged patient survival, most of which are a combination of a proteasome inhibitor + an immunomodulatory drug (ie. billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.

Food and Drug Administration 59

Food and Drug Administration Sales FDA Marketing 59

Pharmaceutical Technology

MARCH 23, 2023

The drug is currently licensed in combination with chemotherapy for patients with classical Hodgkin lymphoma, both as frontline therapy and for those at risk of progressing or having progressed following stem cell transplantation. Seagen generated almost $2 billion in revenue in 2022, an increase approaching 25% from 2021.

Sales 59

Sales Engineering Patients Marketing 59

European Pharmaceutical Review

MAY 2, 2023

We believe that this acquisition will enable us to deliver greater value to patients with ocular diseases at high risk of blindness,” stated Naoki Okamura, President and CEO of Astellas. Avacincaptad pegol is forecasted to achieve sales of $1.09 billion in 2028, according to GlobalData’s Pharma Intelligence Center.

Food and Drug Administration 52

Food and Drug Administration Pharma Sales FDA 52

Pharmaceutical Technology

MARCH 30, 2023

On the same day, researchers presented new interim data from the Phase III RUBY trial of GSK’s PD-1 antibody Jemperli (dostarlimab) in patients with primary advanced or recurrent endometrial cancer. In 2022, the company reported Keytuda sales of $20.9 billion in 2028. billion in its FY 2022 results.

Food and Drug Administration 52

Food and Drug Administration FDA Sales Food 52

pharmaphorum

AUGUST 2, 2022

According to McKinsey, global oncology sales are expected to hit $250 billion by 2024 and, despite the impact of COVID-19, the number of clinical trials starts reached record highs in 2021, stated IQVIA. billion in revenue last year. Development of the compound was subsequently ended.

Marketing 98

Marketing Prospecting Sales Pharma 98

Pharmaceutical Technology

DECEMBER 16, 2022

GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively. of 7MM sales.

Marketing 59

Marketing Side effects Sales Safety 59

pharmaphorum

JANUARY 5, 2023

Recruiting and retaining talent is one of the biggest challenges facing the industry now through 2028, as the US Bureau of Labor Statistics expects life, physical, and social sciences to grow 7%. As the industry continues to grow and evolve, the demand for skilled labour is paramount. About the author.

Pharmaceutical 90

Pharmaceutical Recruitment Training Education 90

Pharmaceutical Technology

JANUARY 19, 2023

While allogeneic hematopoietic stem cell transplants (HSCT) provide long-term benefit to a subset of AML patients, other cell therapy modalities such as natural killer (NK) cells or chimeric antigen receptor (CAR)-T cells have failed to show conclusive benefit in late-stage clinical trials.

Marketing 52

Marketing Sales FDA Management 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. The biggest impacts are likely to be felt by patients with PDPs that use coinsurance, which most plans do for specialty drugs.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Pharmaceutical Technology

OCTOBER 28, 2022

According to GlobalData, Pharmaceutical Technology’s parent company, Prevnar 13 and Vaxneuvance are forecasted to have global sales of $7.26 billion and $812 million in 2028. VAX-24 has forecasted sales of $21 million in the same year. Further plans in the making.

Training 64

Training Marketing Competition FDA 64

Pharmaceutical Technology

AUGUST 22, 2022

When it comes to pharmaceutical, nutritional or cosmeceutical dosing, some of the most crucial parameters are safety, product effectiveness and patient adherence. Softgel capsules, containing a liquid, paste or emulsion active ingredient, are trusted and favoured by many patients. billion by 2028, at a CAGR of 12.6%.

Prescription 52

Prescription Safety Patients Pharmaceutical 52

Pharmaceutical Technology

FEBRUARY 13, 2023

GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028. All patients had received CDK4/6 inhibitors, and 79% had received AstraZeneca’s ER non-PROTAC degrader Faslodex (fulvestrant). Among 44 patients with measurable disease, two had confirmed partial responses.

Competition 59

Competition Safety Patients Pharmaceutical 59

PM360

APRIL 7, 2023

Pharma, formulary decision-makers, and contracting specialists must now track exact dates when drugs became available, then track the difference between average sales price (ASP) and Maximum Fair Price (MFP) to ensure provider reimbursement is correct.” Impact Beyond Medicare The IRA won’t just impact negotiation with the government either.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

Clarivate

AUGUST 27, 2024

and ramped up sales of PFA systems in Europe. In our September 2023 report on the electrophysiology market, Clarivate projected that by 2028, PFA would represent 50% of the U.S. In addition, the improved safety profile of PFA is making the cost-benefit of ablation an easier calculation for many patients. s Farapulse.

Marketing 52

Marketing FDA Competition Medical 52

Pharmaceutical Representative Training

JANUARY 29, 2025

These high prices are the result of multiple factors: theyre derived from living organisms making them sensitive and complex for both manufacturers and patients, research requires advanced technology to test for safety and effectiveness, and theyre in high demand without much competition. The Cost-Saving Alternative: What are Biosimilars?

Marketing 52

Marketing Healthcare Healthcare Physicians 52

Contrarian Sales Techniques

FEBRUARY 10, 2023

They are designed to be safe and comfortable for patients, and typically have minimal side effects. According to various market research reports, the global non-invasive medical devices market was valued at approximately USD 45 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of over 6% from 2021 to 2028.

Healthcare 52

Healthcare Healthcare Manufacturing Medical 52

Medico Reach

JUNE 2, 2022

With over 40 years of experience, the company has helped many dental practices provide the best solutions to patients. They follow a direct sales model and sell their products directly to the customer, without any interference from any middlemen. between 2021-2028. Also, choose a company based on its specialty that suits you.

Marketing 52

Marketing Manufacturing Distribution Leads 52

Pharmaceutical Technology

MAY 30, 2023

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028. Similarly, Almirall S.A.,

Sales 105

Sales Marketing Prescription Pharma 105

pharmaphorum

AUGUST 8, 2022

As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer’s marketing muscle – plus a phase 3 antibody candidate, a phase 1 follow-up to Oxbryta that could offer improved dosing. per-share deal valuing GBT at $5.4

Marketing 111

Marketing Sales Pharma FDA 111

World of DTC Marketing

MARCH 17, 2021

sales until at least 2023 because 257 patent filings stand in the way. Another biologic, Enbrel, on the market since 1998, will not have its $5 billion in sales challenged until the end of 2028. Billions in excess drug costs are shouldered by employers, taxpayers and patients as a result.

Pharma 186

Pharma Competition Prescription Sales 186

pharmaphorum

OCTOBER 10, 2022

The results of the STELLAR trial showed that the activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein achieved a significant increase in exercise capacity measured using the six-minute walking test in PAH patients when added to stable background therapy, hitting its primary objectives.

Sales 52

Sales FDA Pharma Competition 52

European Pharmaceutical Review

MARCH 25, 2025

billion, alongside net sales royalties if HRS-5346 is approved. MSD intends to commit a further $8 billion of US capital investment by 2028, the firm shared. Ltd (Hengrui Pharma) has agreed to license its drug candidate HRS-5346 worldwide, excluding the Greater China region.As

Manufacturing 52

Manufacturing Pharma Recruitment Pharmaceutical 52

Pharmaceutical Technology

MAY 26, 2023

These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. The surveyed physicians believed that both newly-diagnosed, and treatment-refractory patients are the most likely to benefit from such therapies. This high compound annual growth rate of 23.6%

Marketing 105

Marketing Physicians Insurance Pharmaceutical 105

PM360

SEPTEMBER 28, 2022

Patient behavior on insulin: Part D plans will have limited opportunity to adjust strategy for 2023, given bids are locked in. Behavioral response (patient adherence/persistence) to a lower out-of-pocket cost for insulin is unknown. Maximum patient Part D out-of-pocket set at $2,000. Cost sharing “smoothing” becomes available.

Manufacturing 97

Manufacturing Government Prescription Marketing 97